HALİT KANCA, KÜBRA KARAKAŞ ALKAN

Effectiveness of aglepristone at lower-than-standard doses in prevention of pregnancy in mismated bitches

Bu çalışmanın amacı, köpeklerde istenmeyen çiftleşmeler sonrası gebeliğin engellenmesi amacıyla farklı dozlarda uygulanan aglepristonun klinik etkinliğinin araştırılmasıdır. Bu amaçla, çiftleşmenin doğrulandığı 48 dişi köpek materyal olarak kullanıldı. Köpekler rastgele 4 gruba ayrılarak uygulama gruplarında, diöstrusun ilk 10 günü içerisinde 24 saat arayla 2 kez 5 mg/kg (grup I, n=12), 7.5 mg/kg (grup II, n=12) veya 10 mg/kg (grup III, n=12) dozunda aglepriston uygulandı. Oniki köpek (grup IV) kontrol grubunu oluşturdu. Gebelik muayenesi diöstrusun 30. gününde ultrasonografik yöntemle gerçekleştirildi. İlk ilaç uygulamasının 0, 3 ve 7. günleri ile ultrasonografik muayene günü alınan kan örneklerinde plazma progesteron konsantrasyonları radioimmunoassay yöntemiyle belirlendi. Grup I’de bir köpek dışında aglepriston uygulanan köpeklerin hiçbirinde gebelik belirlenmedi. Kontrol grubunda gebelik oranı %83.3 olarak belirlendi. Çalışma gruplarında ortalama plazma progesteron konsantrasyonları 0 ve 3. günlerde belirgin değişiklik göstermedi (P0,01). Aglepriston uygulaması grupların tümünde interöstrus aralığının kısalması ile sonuçlandı (grup I: 15.33±5.29 gün; grup II: 12.78±4.94 gün; grup III: 14.45±4.29 gün, P>0.05). Aglepriston uygulanan 20 adet köpek takip eden östrusta çiftleştirildi ve %90 gebelik oranı saptandı. Standarttan daha düşük dozlarda uygulanan aglepristonun istenmeyen çiftleşmeler sonrası gebeliğin engellenmesinde etkili olduğu ve uygun maliyetli bir tedavi seçeneği sunduğu sonucuna varıldı.

Anahtar Kelimeler:

ultrasonografi, dişi köpek, diöstrüs, dozaj etkileri, ilaç tedavisi, kızgınlık, farmakodinamik, farmakokinetik, gebelik, gebelik komplikasyonları, gebelik oranları, progesteron, üreme randımanı, dölverim performansı, üreme özellikleri

Köpeklerde istenmeyen çiftleşmeleri takiben gebeliğin engellenmesinde standarttan düşük dozlarda aglepristonun etkinliğinin araştırılması

The objective of this study was to evaluate the clinical efficacy of three different doses of aglepristone administered in early diestrus for prevention of pregnancy in mismated dogs. A total of 48 mismated, copulation confirmed bitches were used as material. Bitches were randomly allocated into one of four groups and treatment groups received 5 mg/kg (group I, n=12), 7.5 mg/kg (group II, n=12) or 10 mg/kg (group III, n=12) of aglepristone by two injections, 24 h apart within 10 days of diestrus. Twelve bitches (group IV) served as controls. Pregnancy was assessed by ultrasonography on day 30 of diestrus. Blood samples were collected for determination of plasma progesterone concentrations by radioimmunoassay on days 0, 3 and 7 of first aglepristone administration and on the day of ultrasonographic examination. None of aglepristone treated bitches except for one bitch in group I became pregnant. Pregnancy rate in the control group was 83.3%. There was no significant difference between mean plasma progesterone concentrations in study groups on day 0 and 3 (P>0.05). On day 30 of diestrus, plasma concentrations of progesterone were significantly lower in aglepristone treated bitches (group I: 92.60±5.74 nmol/L; group II: 85.66±3.69 nmol/L; group III: 78.87±4.86 nmol/L) compared to controls (110.62±6.24 nmol/L, P<0.01). Aglepristone administration resulted in shortening of interestrus interval in all groups (group I: 15.33±5.29 days; group II: 12.78±4.94 days and group III: 14.45±4.29 days, P>0.05). Twenty aglepristone treated bitches were bred in the subsequent estrus and overall pregnancy rate obtained was 90%. In conclusion, aglepristone at lower-than-standard doses administered in early diestrus effectively prevents pregnancy in mismated bitches and potentially offers a cost-effective treatment option.

Keywords:

ultrasonography, bitches, dioestrus, dosage effects, drug therapy, oestrus, pharmacodynamics, pharmacokinetics, pregnancy, pregnancy complications, pregnancy rate, progesterone, reproductive efficiency, reproductive performance, reproductive traits,

PDF

___

1. Eilts BE: Pregnancy termination in the bitch and queen. Clin Tech Small Anim Pract, 17, 116-123, 2002.
2. Weiss DJ, Klausner JS: Drug-associated aplastic anemia in dogs: Eight cases (1984-1988). J Am Vet Med Assoc, 196, 472-475, 1990.
3. Sutton DJ, Geary MR, Bergman JG: Prevention of pregnancy in bitches following unwanted mating: A clinical trial using low dose oestradiol benzoate. J Reprod Fertil Suppl, 51, 239-243, 1997.
4. Wanke MM, Romagnoli S, Verstegen J, Concannon PW: Pharmacological approaches to pregnancy termination in dogs and cats including the use of prostaglandins, dopamine agonists, and dexamethasone. In, Concannon PW, England G, Verstegen J, Linde- Forsberg C (Eds): Recent Advances in Small Animal Reproduction. International Veterinary Information Service (www.ivis.org), Ithaca, New York, USA, 2002.
5. Johnston SD, Kustritz VR, Olson PNS: Prevention and termination of canine pregnancy. In, Johnston SD, Kustritz VR, Olson PNS (Eds): Canine and Feline Theriogenology. pp.168-192, WB Saunders Company, Philedelphia, 2001.
6. Sokolowski JH: The effects of ovariectomy on pregnancy maintenance in the bitch. Lab Anim Sci, 21, 696-699, 1971.
7. Hoffman B, Schuler G: Receptor blockers-general aspects with respect to their use in domestic animal reproduction. Anim Reprod Sci, 60-61, 295-312, 2000.
8. Fieni F, Tainturier D, Bruyas JF, Badinand F, Berthelot X, Ronsin P, Rachail M, Lefay MP: Etude clinique d’une antihormone pour provoquer l’avortement chez la chienne: L’agle´pristone. Rec Med Vet, 172, 359-367, 1996.
9. Fieni F, Marnet PG, Martal J, Siliart B, Riou F, Bernard F, Riou M, Bruyas JF, Tainturier D: Hormonal variation in bitches after early and mid-pregnancy termination with aglepristone (RU 534). J Reprod Fertil Suppl, 57, 245-250, 2001.
10. Kanca H, Walter I, Schafer-Somi S, Budik S, Izgur H, Aslan S: Induction of abortion with aglepristone significantly changed the expression of progesterone and estrogen receptors in canine endometrial stromal cells. Theriogenology, 70, 1439-1448, 2008.
11. Fieni F, Bruyas JF, Battut I, Tainturier D: Clinical use of anti-progestins in the bitch. In, Concannon PW, England G, Verstegen J, Linde-Forsberg C (Eds): Recent Advances in Small Animal Reproduction. International Veterinary Information Service (www.ivis.org), Ithaca, New York, USA, 2001.
12. Schafer-Somi S, Klein D, Beceriklisoy HB, Sabitzer S, Ay SS, Agaoglu AR, Kücükaslan I, Kaya D, Aksoy OA, Aslan S: Uterine progesterone receptor and leukaemia inhibitory factor mRNA expression in canine pregnancy. Reprod Domest Anim, 44 (2): 109-114, 2009.
13. Concannon PW, McCann JP, Temple M: Biology and endocrinology of ovulation, pregnancy and parturition in the dog. J Reprod Fertil Suppl, 39, 3-25, 1989.
14. Whitacre MD, Yates DJ, VanCamp SD, Meuten DJ: Detection of intravaginal spermatozoa in the bitch. Vet Clin Pathol, 21, 85-87, 1992.
15. Alacam E, Ay SS, Saban E: The evaluation of various radioimmuno-assay progesterone kits for different stage of reproductive period in the cow, sheep and bitch. Vet J Ankara Univ, 56, 37-41, 2009.
16. Wiebe VJ, Howard JP: Pharmacologic advances in canine and feline reproduction. Top Companion Anim M, 24 (2): 71-99, 2009.
17. Feldman EC, Davidson AP, Nelson RW, Nyland TG, Munro C: Prostaglandin induction of abortion in pregnant bitches after misalliance. J Am Vet Med Assoc, 202, 1855-1858, 1993.
18. Fieni M, Fuhrer D, Tainturier JF, Bruyas, Dridi S: Use of PGF2α analog, cloprostenol, for pregnancy termination in dogs. J Reprod Fertil Suppl, 39, 332-333, 1989.
19. Daurio CP, Gilman MR, Pulliam JD, Seward RL: Reproductive evaluation of male Beagles and safety of ivermectin. Am J Vet Res, 48, 1755-1760, 1987.
20. Linde-Forsberg C, Forsberg M: Results of 527 controlled artificial inseminations in dogs. J Reprod Fertil Suppl, 47, 313-323, 1993.
21. England GCW, Allen WE: Seminal characteristics and fertility in dogs. Vet Rec, 125, 339, 1989.
22. Philibert D: RU 46534. Affinité relative de liaison pour les récepteurs stéroïdiens-activité antiprogestérone in vivo. Rapport d’étude interne Roussel Uclaf, 1994.
23. Johnston SD, KIang DT, Seguin BE, Hegstad RL: Cytoplasmic estrogen and progesterone receptors in canine endometrium during the estrous cycle. Am J Vet Res, 46, 1653-1658, 1985.
24. Heikinheimo O, Haukkamaa M, Lahteenmaki P: Distribution of RU486 and its demethylated metabolites in human. J Clin Endocrinol Metab, 68, 270-275, 1989.
25. Sarkar NN: Mifepristone: Bioavailability, pharmacokinetics and use-effectiveness. Eur J Obstet Gyn R B, 101, 113-120, 2002.
26. Galac S, Kooistra HS, Dieleman SJ, Cestnik V, Okkens AC: Effects of aglepristone, a progesterone receptor antagonist, administered during the early luteal phase in non-pregnant bitches. Theriogenology, 62, 494-500, 2004.
27. Polisca A, Scotti L, Orlandi R, Brecchia G, Maranesi M, Zerani M, Boiti C: Aglepristone (RU534) administration to non-pregnant bitches in the mid-luteal phase induces early luteal regression. Theriogenology, 74, 672-681, 2010.
28. Okkens AC, Kooistra HS: Anoestrus in the dog: A fascinating story. Reprod Domest Anim, 41, 291-296, 2006